This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $299,504 to Imetabolic Biopharma Corp to develop a novel therapeutic approach for clearing small dense LDL (sdLDL) particles from the circulation. The project aims to reengineer a proprietary ApoC-III antagonist to include bioactive ApoE mimetic peptides, creating a dual-domain therapeutic candidate that can specifically recognize and bind to sdLDL particles, facilitating their clearance via LDL receptor and heparin sulfate proteoglycan uptake pathways. This proof-of-concept Phase I work focuses on demonstrating a 5-fold increase in cellular uptake of purified human sdLDL particles and a 10% reduction in apolipoprotein B levels in the surrounding biological milieu compared to controls. Successful completion of this milestone would lead to a Phase 2 application for further evaluation, manufacturing, and preclinical testing of the therapeutic candidate.
Generated 3/18/25, 3:55 AM